R. Dewji

796 total citations
9 papers, 628 citations indexed

About

R. Dewji is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, R. Dewji has authored 9 papers receiving a total of 628 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 3 papers in Pulmonary and Respiratory Medicine and 2 papers in Molecular Biology. Recurrent topics in R. Dewji's work include PARP inhibition in cancer therapy (5 papers), Sarcoma Diagnosis and Treatment (3 papers) and Vascular Tumors and Angiosarcomas (2 papers). R. Dewji is often cited by papers focused on PARP inhibition in cancer therapy (5 papers), Sarcoma Diagnosis and Treatment (3 papers) and Vascular Tumors and Angiosarcomas (2 papers). R. Dewji collaborates with scholars based in United Kingdom, Netherlands and Italy. R. Dewji's co-authors include Mark R. Middleton, Ruth Plummer, Hilary Calvert, Richard H. Wilson, Diane Wang, Nicola J. Curtin, Neil Steven, Paul Lorigan, Adrian L. Harris and Peter J. McHugh and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and European Journal of Cancer.

In The Last Decade

R. Dewji

9 papers receiving 620 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R. Dewji United Kingdom	7	528	403	96	83	77	9	628
Jeffrey Evans United Kingdom	6	336 0.6×	275 0.7×	33 0.3×	50 0.6×	53 0.7×	6	421
A. D. Colevas United States	10	391 0.7×	355 0.9×	113 1.2×	17 0.2×	40 0.5×	24	652
Jorge D. Gallo United States	10	337 0.6×	355 0.9×	127 1.3×	28 0.3×	37 0.5×	23	558
Marta Castroviejo‐Bermejo Spain	3	395 0.7×	286 0.7×	85 0.9×	52 0.6×	55 0.7×	3	503
Valentina E. Schneeberger United States	8	612 1.2×	587 1.5×	143 1.5×	43 0.5×	81 1.1×	11	862
Hiroaki Fujimori Japan	15	281 0.5×	462 1.1×	70 0.7×	15 0.2×	44 0.6×	25	619
Amanda Balboni Iniguez United States	7	207 0.4×	470 1.2×	130 1.4×	9 0.1×	33 0.4×	7	604
Kårstein Måseide Norway	7	201 0.4×	301 0.7×	71 0.7×	11 0.1×	20 0.3×	10	456
Kyung-Hun Lee South Korea	10	270 0.5×	293 0.7×	64 0.7×	14 0.2×	25 0.3×	13	434
Robert J. Cardnell United States	7	400 0.8×	311 0.8×	112 1.2×	21 0.3×	112 1.5×	15	601

Countries citing papers authored by R. Dewji

Since Specialization

Citations

This map shows the geographic impact of R. Dewji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Dewji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Dewji more than expected).

Fields of papers citing papers by R. Dewji

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Dewji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Dewji. The network helps show where R. Dewji may publish in the future.

Co-authorship network of co-authors of R. Dewji

This figure shows the co-authorship network connecting the top 25 collaborators of R. Dewji. A scholar is included among the top collaborators of R. Dewji based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Dewji. R. Dewji is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Boellaard, Ronald, Wouter V. Vogel, Felix M. Mottaghy, et al.. (2015). Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial. European Journal of Nuclear Medicine and Molecular Imaging. 42(6). 848–857. 19 indexed citations

Duffaud, Florence, Stefan Sleijfer, Saskia Litière, et al.. (2015). Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials. European Journal of Cancer. 51(17). 2615–2623. 31 indexed citations

Frezza, Anna Maria, Charlotte Benson, Ian Judson, et al.. (2014). Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience. PubMed. 4(1). 7–7. 41 indexed citations

Plummer, Ruth, Paul Lorigan, Neil Steven, et al.. (2013). A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemotherapy and Pharmacology. 71(5). 1191–1199. 143 indexed citations

Plummer, Ruth, Christopher J. Jones, Mark R. Middleton, et al.. (2008). Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors. Clinical Cancer Research. 14(23). 7917–7923. 298 indexed citations

Plummer, Ruth, Paul Lorigan, Jonathan J. Evans, et al.. (2006). First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). Journal of Clinical Oncology. 24(18_suppl). 8013–8013. 82 indexed citations

Plummer, Ruth, Jonathan J. Evans, Neil Steven, et al.. (2006). A phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). Melanoma Research. 16(Supplement 1). S82–S82. 5 indexed citations

Plummer, E. Ruth, Mark R. Middleton, R. Wilson, et al.. (2005). Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AG014699, in combination with temozolomide. Clinical Cancer Research. 11. 6 indexed citations

Verweij, Jaco J., André Planting, M. van der Burg, et al.. (1993). Phase I study on 4-weekly 6 hour infusion of BMY-25067 in patients (PTS) with solid tumors. European Journal of Cancer. 29. S119–S119. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact